Skip to main content

Table 3 Between-gender differences combining HIGH and LOW group participants for self-reported measures, including baseline adjustment

From: Most functional outcomes are similar for men and women after hip fracture: a secondary analysis of the enhancing mobility after hip fracture trial

 

Baseline (n = 160)

Week 4 (n = 158)

Week 4-baseline (n = 158)

Week 16 (n = 150)

Week 16-baseline (n = 150)

Self-rated mobility as good*

1.2 (0.5 to 3.4), 0.690

1.0 (0.5 to 2.4), 0.940

1.0 (0.4 to 2.3), 0.999

0.5 (0.2 to 1.1), 0.082†∫

0.5 (0.2 to 1.1), 0.078†∫

Self-rated strength as good*

0.8 (0.2 to 2.4), 0.632

0.4 (0.1 to 1.3), 0.136

0.4 (0.1 to 1.4), 0.155

0.6 (0.3 to 1.5), 0.310†∫

0.7 (0.3 to 1.7), 0.387†∫

Self-rated balance as good*

0.9 (0.4 to 2.0), 0.718

1.0 (0.4 to 2.4), 0.940

1.0 (0.4 to 2.6), 0.953

0.8 (0.3 to 1.9), 0.611†∫

0.9 (0.4 to 2.0), 0.711†∫

Self-rated pain as none or slight*

0.8 (0.3 to 1.9), 0.602

0.7 (0.3 to 1.6), 0.450

0.8 (0.3 to 1.7), 0.505

1.0 (0.4 to 2.5), 0.920

1.1 (0.5 to 2.6), 0.887

Self-rated health as worse*

1.0 (0.4 to 2.1), 0.899

0.9 (0.4 to 2.0), 0.772§

0.9 (0.4 to 2.0), 0.785§

0.7 (0.3 to 1.9), 0.476

0.8 (0.3 to 2.1), 0.605

Modified falls efficacy scale

10.3 (-2.3 to 22.8), 0.109†‡

8.4 (-3.8 to 20.7), 0.174†§

3.7 (-7.3 to 14.6), 0.507†ǁ

4.7 (-9.8 to 19.3), 0.520†∫

-0.7 (-13.8 to 12.4), 0.916**

EQ5D

0.02 (-0.09 to 0.1), 0.765

0.04 (-0.07 to 0.2), 0.510

0.03 (-0.07 to 0.1), 0.535

-0.03 (-0.2 to 0.09), 0.610†∫

-0.04 (-0.2 to 0.08), 0.529†∫

  1. Results as mean (95% CI), p unless *indicating results as odds ratio (CI 95%), p; indicates men performed better than women; n = 158; §n = 157; ǁn = 155; n = 149; **n = 146.